Monday, November 7, 2016

Thalidomide: Arlene Foster agrees to support German compensation claim

First Minister Arlene Foster agrees to support Thalidomide victims seeking compensation for victims from the German government.

Roche says flexible pricing ready for cancer, not MS drugs

ZURICH (Reuters) - The spotlight on finding a cancer cure has spurred improvements in systems to collect and analyze oncology data, but efforts to track patients with other diseases lag behind, Roche pricing head Jens Grueger said.

U.S. Senate panel urges FTC to launch antitrust probe of Mylan

A file photo showing the EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company are seen in WashingtonBy Sarah N. Lynch WASHINGTON (Reuters) - The U.S. Senate Judiciary Committee urged federal antitrust regulators on Monday to launch a probe into whether EpiPen maker Mylan NV broke the law by preventing schools from purchasing competing allergy treatments. The bipartisan request to the Federal Trade Commission by Senate Judiciary Chairman Charles Grassley and Ranking Member Patrick Leahy comes just a few weeks before the committee is slated to convene a hearing to scrutinize a pending $465 million settlement that Mylan has said will resolve claims it underpaid rebates to state and federal Medicaid programs. Previously, schools that wished to purchase additional EpiPens could do so in some cases with a discount and a "limited purchase restriction," but no such restriction remains in place today, she added.

Friday, November 4, 2016

Men's long working hours, short sleep may harm health in old age

(Reuters Health) – Working long hours and skimping on sleep in midlife may lead to poorer physical health in old age, according to a study from Finland.

CMS revokes Alere unit's Medicare enrollment

Diagnostic company Alere Inc said on Friday the Medicare enrollment of one of its units had been revoked effective Nov. 4 by the Centers for Medicare and Medicaid Services (CMS), which said the unit had submitted claims for 211 dead patients. Shares of Alere, which is being bought by Abbott Laboratories, fell as much as 16 percent in heavy trading. The CMS sent the unit, Arriva Medical LLC, a notice on Oct. 5 and revoked the unit's enrollment after Alere unsuccessfully appealed the decision on Nov. 2, Alere disclosed in a regulatory filing.

Thursday, November 3, 2016

Tuesday, November 1, 2016

From gene editing to death traps, Seattle scientists innovate in race to end malaria

By Kieran Guilbert SEATTLE (Thomson Reuters Foundation) - When Kayode Ojo first fell sick with malaria as a young boy in Nigeria, his grandfather shunned modern medicine, venturing into the bush to search for herbs and plants to treat the disease. Having succumbed to malaria a further 50 or more times in his life, the United States-based scientist, now in his forties, is determined that his research - to develop a drug to stop transmission from humans back to mosquitoes - will help to eradicate the deadly disease. "When people in Nigeria, the world's hardest-hit country, get malaria, many simply shrug their shoulders and see it as normal ... that needs to change," Ojo told the Thomson Reuters Foundation in a lab at the University of Washington in Seattle.